The purpose of this study was to examine the possible effects of in vivo morphine (Mor) treatments on macrophage involvement in the mediation of reductions in T-cell functions. Male BALB/c mice were exposed to multiple sc injections of Mor in increasing doses twice a day for 4 days. T-lymphocyte proliferation in response to alloantigen was significantly affected by Mor, while Mor treatment failed to suppress PMA/A23187-induced macrophagedepleted lymphocyte proliferation. Interestingly, after separation of lymphocytes and macrophages from control or Mor-treated mice, Con A-stimulated T-cell proliferation was suppressed only when Mor-treated macrophages were combined with control or Mor-treated lymphocytes. Further, addition of exogenous interleukin (IL)-1 and IL-2 promoted the proliferative responses of lymphocytes obtained from Mor-treated mice to Con A. Studies of the mechanism of suppression show that macrophages are the primary target cells, since macrophage-depleted lymphocyte preparations produced little suppression, and that prostaglandin E 2 and reactive oxygen intermediates (ROI) are important mediators possessing immunoinhibitory activities, since indomethacin or scavengers of ROI abrogated the suppression. These results demonstrate that Mor-triggered release of inhibitory macrophage metabolites and decrement in soluble cytokines production are involved in the immunosuppressive effects caused by subchronic in vivo repetitive administrations of the drug of abuse.
INTRODUCTION
The growing interest in detecting the relationship between drug abuse and immunocompetence has made clear that morphine (Mor), marijuana, cocaine, and psychomimetic drugs (e.g., phencyclidine and alprazolam) interfere with several immune responses. Opiate drugs have been known to alter a number of immune parameters in both humans and experimental animals. For instance, in vivo administrations of morphine have been reported to produce a suppression of mitogenic responses, a reduced antibody production, and an inhibition of both natural killer cell activity and delayedtype hypersensitivity (Eisenstein, Taub, Adler, & Rogers, 1991; Ho, Cheung, Leung, & Wen, 1986) . Concurrently, morphine treatment in vivo causes an increase in tumor growth and an increase in mortality in mice infected with Toxoplasma gondii or Friend virus (Chao, Sharp, Pomeroy, Filice, & Peterson, 1990; Starec, Rouveix, Sinet, Chau, Desforges, Pocidalo, & Lechat, 1991) . In our previous studies, a stable model of mouse dependence has been established by twice daily, subchronic, subcutaneous (sc) injections of morphine for 4 days, which were gradually increased from 20 to 50 mg/ kg. Macrophages (Mfs) of addicted mice so treated have a lower ability to phagocytose neutral red, to induce interleukin (IL)-1 and tumor necrosis factor (TNF) production, and kill tumor S180 cultured cells (Lu & Lin, 1994) . Also, the model mice exhibited
